Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|Glioma Lymphoma Metastatic Malignant Solid Neoplasm Neuroendocrine Neoplasm Recurrent Adult Soft Tissue Sarcoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Chronic Lymphocytic Leukemia Recurrent Colorectal Carcinoma Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Head and Neck Carcinoma Recurrent Lung Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Pancreatic Carcinoma Recurrent Prostate Carcinoma Recurrent Renal Cell Carcinoma Recurrent Thyroid Gland Carcinoma Refractory Chronic Lymphocytic Leukemia Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Stage III Breast Cancer Stage III Colorectal Cancer AJCC v7 Stage III Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage III Prostate Cancer Stage III Renal Cell Cancer Stage III Skin Melanoma Stage III Soft Tissue Sarcoma Stage IIIA Breast Cancer Stage IIIA Colorectal Cancer AJCC v7 Stage IIIA Skin Melanoma Stage IIIB Breast Cancer Stage IIIB Colorectal Cancer AJCC v7 Stage IIIB Skin Melanoma Stage IIIC Breast Cancer Stage IIIC Colorectal Cancer AJCC v7 Stage IIIC Skin Melanoma Stage IV Breast Cancer Stage IV Colorectal Cancer AJCC v7 Stage IV Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IV Prostate Cancer Stage IV Renal Cell Cancer Stage IV Skin Melanoma Stage IV Soft Tissue Sarcoma Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Unresectable Solid Neoplasm||Other: Pharmacological Study Drug: Romidepsin||Phase 1|
|Study Design:||Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction|
- Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 [ Time Frame: 28 days ]In order to define levels of hepatic impairment at which dose modifications of romidepsin are required, data will be combined across hepatic dysfunction groups to evaluate the association between toxicity, dose, and liver assay level(s). The outcome variable, drug tolerance and dose-limiting toxicities will be modeled as function of dose and liver assay using multivariate linear regression. Higher order terms of the predictor variables and interactions will be included if there is evidence of non-linear and/or non-additive associations.
- Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 [ Time Frame: 28 days ]Analyses will be descriptive in nature. The observed toxicities will be characterized by dose level within each category of liver dysfunction (mild, moderate, severe, and liver transplant). These results will be summarized in relation to what is known about romidepsin in a population without liver dysfunction (as defined in this protocol).
- Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method [ Time Frame: 0, 1, 2, 3, 4, 4.25, 4.5, 5, 6, 8, 10, 24, and 48 hours after initiation of the infusion on day 1 ]Pharmacokinetic variables will be tabulated and descriptive statistics calculated for each function group. Geometric means and coefficients of variation will be presented for maximum concentration and area under the curve for each group.
- Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria [ Time Frame: Up to 30 days ]Association of antitumor activity and romidepsin treatment will be documented.
- Child-Pugh classification of hepatic dysfunction [ Time Frame: Baseline ]Correlations of the Child-Pugh classification of hepatic dysfunction with the observed toxicities and plasma PK of romidepsin administration will be explored.
|Actual Study Start Date:||June 12, 2012|
|Estimated Study Completion Date:||September 30, 2017|
|Estimated Primary Completion Date:||September 30, 2017 (Final data collection date for primary outcome measure)|
Experimental: Treatment (romidepsin)
Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Other: Pharmacological Study
Correlative studiesDrug: Romidepsin
I. To establish the safety and tolerability of romidepsin given on days 1, 8, and 15 of a 28 day cycle to patients with varying degrees of liver dysfunction (mild, moderate and severe).
II. To establish the maximum tolerated dose (MTD) and appropriate dosing recommendations for romidepsin in such patients.
III. To characterize the pharmacokinetics (PK) of romidepsin in patients with varying degrees of liver dysfunction.
I. To explore correlations of the Child-Pugh classification of liver dysfunction with the observed toxicities and plasma PK of romidepsin administration.
II. To document any preliminary evidence of antitumor activity at tolerable doses of romidepsin in patients with varying degrees of liver dysfunction.
OUTLINE: This is a dose-escalation study.
Patients receive romidepsin intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01638533
|United States, California|
|City of Hope Comprehensive Cancer Center||Suspended|
|Duarte, California, United States, 91010|
|University of California Davis Comprehensive Cancer Center||Active, not recruiting|
|Sacramento, California, United States, 95817|
|City of Hope South Pasadena||Recruiting|
|South Pasadena, California, United States, 91030|
|Contact: Stephen C. Koehler 626-396-2900 firstname.lastname@example.org|
|Principal Investigator: Stephen C. Koehler|
|United States, Georgia|
|Emory University/Winship Cancer Institute||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Contact: Olatunji B. Alese 404-778-1868|
|Principal Investigator: Olatunji B. Alese|
|United States, Illinois|
|University of Chicago Comprehensive Cancer Center||Suspended|
|Chicago, Illinois, United States, 60637|
|United States, Maryland|
|Johns Hopkins University/Sidney Kimmel Cancer Center||Suspended|
|Baltimore, Maryland, United States, 21287|
|National Cancer Institute Developmental Therapeutics Clinic||Suspended|
|Bethesda, Maryland, United States, 20892|
|National Institutes of Health Clinical Center||Active, not recruiting|
|Bethesda, Maryland, United States, 20892|
|United States, Michigan|
|Wayne State University/Karmanos Cancer Institute||Suspended|
|Detroit, Michigan, United States, 48201|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Paul Haluska 507-284-2511 email@example.com|
|Principal Investigator: Paul Haluska|
|United States, Ohio|
|Case Western Reserve University||Withdrawn|
|Cleveland, Ohio, United States, 44106|
|United States, Pennsylvania|
|Penn State Milton S Hershey Medical Center||Suspended|
|Hershey, Pennsylvania, United States, 17033-0850|
|Thomas Jefferson University Hospital||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Marlana M. Orloff 215-955-6084|
|Principal Investigator: Marlana M. Orloff|
|United States, Wisconsin|
|University of Wisconsin Hospital and Clinics||Recruiting|
|Madison, Wisconsin, United States, 53792|
|Contact: Roisin M. Connolly 410-614-9217 firstname.lastname@example.org|
|Principal Investigator: Roisin M. Connolly|
|University Health Network-Princess Margaret Hospital||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Contact: Lillian L. Siu 416-946-4501 email@example.com|
|Principal Investigator: Lillian L. Siu|
|Principal Investigator:||Roisin Connolly||JHU Sidney Kimmel Comprehensive Cancer Center LAO|